DNP - Der Neurologe und Psychiater

, Volume 15, Issue 5, pp 40–51 | Cite as

Management von Nebenwirkungen für eine positive Langzeitprognose

Psychopharmakotherapie
Fortbildung
  • 52 Downloads

Zusammenfassung

Für die Therapie schwerer psychischer Erkrankungen sind Psychopharmaka unverzichtbar. Da diese Substanzen häufig Nebenwirkungen aufweisen, ist eine kritische Indikationsstellung und Nutzen-Risiko-Bewertung erforderlich. Vor allem potenzielle Risiken, die eine Langzeitprognose negativ beeinflussen können, sollten rasch identifiziert und möglichst eliminiert werden.

Literatur

  1. 1.
    Schwabe U: Arzneiverordnungs-Report 2013. Berlin, Heidelberg, Springer-Verlag, 2013.Google Scholar
  2. 2.
    Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011; 108(41):687–693.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments metaanalysis. Lancet 2013; 382(9896):951–962.PubMedCrossRefGoogle Scholar
  4. 4.
    Ray WA, Chung CP, Murray KT, Hall K, Stein CM: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360(3):225–235.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH: QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC: Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170(6):642–650.PubMedCrossRefGoogle Scholar
  7. 7.
    Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR: Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2002;(1):CD001950.PubMedGoogle Scholar
  8. 8.
    Dumon JP, Catteau J, Lanvin F, Dupuis BA: Randomized, double-blind, crossover, placebo- controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149(5):647–650.PubMedGoogle Scholar
  9. 9.
    Lima AR, Weiser KV, Bacaltchuk J, Barnes TR: Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2004;(1):CD003727.PubMedGoogle Scholar
  10. 10.
    Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A: Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58(7):318–322.PubMedCrossRefGoogle Scholar
  11. 11.
    El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K: Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;(1):CD000458.PubMedGoogle Scholar
  12. 12.
    Leung JG, Breden EL: Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011; 45(4):525–531.PubMedCrossRefGoogle Scholar
  13. 13.
    Silver H, Geraisy N, Schwartz M: No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a doubleblind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995; 56(4):167–170.PubMedGoogle Scholar
  14. 14.
    Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N, Di Rosa AE, Morgante L: Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 2006; 29(5):265–268.PubMedCrossRefGoogle Scholar
  15. 15.
    Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C: Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2008; 69(4):546–554.PubMedCrossRefGoogle Scholar
  16. 16.
    Soares-Weiser K, Maayan N, McGrath J: Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;(2):CD000209.PubMedGoogle Scholar
  17. 17.
    Miller ER, III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142(1):37–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Soares KV, McGrath JJ: Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;(4):CD000209.PubMedGoogle Scholar
  19. 19.
    Pisani F, Oteri G, Costa C, Di RG, Di PR: Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25(2):91–110.PubMedCrossRefGoogle Scholar
  20. 20.
    Koster M, Grohmann R, Engel RR, Nitsche MA, Ruther E, Degner D: Seizures during antidepressant treatment in psychiatric inpatients—results from the transnational pharmacovigilance project „Arzneimittelsicherheit in der Psychiatrie“ (AMSP) 1993-2008. Psychopharmacology (Berl) 2013; 230(2):191–201.CrossRefGoogle Scholar
  21. 21.
    Alexander J, Nillsen A: Venlafaxine-induced delirium. Aust N Z J Psychiatry 2011; 45(7):606.PubMedCrossRefGoogle Scholar
  22. 22.
    Howe C, Ravasia S: Venlafaxine-induced delirium. Can J Psychiatry 2003; 48(2):129.PubMedGoogle Scholar
  23. 23.
    Bailer U, Fischer P, Kufferle B, Stastny J, Kasper S: Occurrence of mirtazapine-induced delirium in organic brain disorder. Int Clin Psychopharmacol 2000; 15(4):239–243.PubMedCrossRefGoogle Scholar
  24. 24.
    Degner D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR, Schmidt LG: Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 Suppl 1:S39–S45.PubMedGoogle Scholar
  25. 25.
    Grohmann R, Ruther E, Engel RR, Hippius H: Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32(1):21–28.PubMedCrossRefGoogle Scholar
  26. 26.
    Grohmann R, Hippius H, Helmchen H, Ruther E, Schmidt LG: The AMUP study for drug surveillance in psychiatry - a summary of inpatient data. Pharmacopsychiatry 2004; 37 Suppl 1:S16–S26.PubMedCrossRefGoogle Scholar
  27. 27.
    Omata N, Murata T, Omori M, Wada Y: A patient with lithium intoxication developing at therapeutic serum lithium levels and persistent delirium after discontinuation of its administration. Gen Hosp Psychiatry 2003; 25(1):53–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Cavallazzi R, Saad M, Marik PE: Delirium in the ICU: an overview. Ann Intensive Care 2012; 2(1):49.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Prüter C: Delir; in: Frank Block, Christian Prüter, (eds): Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg, Springer Medizin Verlag, 2006, pp 386-405.Google Scholar
  30. 30.
    Bender S, Grohmann R, Engel RR, Degner D, ttmann-Balcar A, Ruther E: Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 2004; 37 Suppl 1:S46–S53.PubMedGoogle Scholar
  31. 31.
    Centorrino F, Albert MJ, Drago-Ferrante G, Koukopoulos AE, Berry JM, Baldessarini RJ: Delirium during clozapine treatment: incidence and associated risk factors. Pharmacopsychiatry 2003; 36(4):156–160.PubMedCrossRefGoogle Scholar
  32. 32.
    Prudent M, Drame M, Jolly D, Trenque T, Parjoie R, Mahmoudi R, Lang PO, Somme D, Boyer F, Laniece I, Gauvain JB, Blanchard F, Novella JL: Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort. Drugs Aging 2008; 25(11):933–946.CrossRefGoogle Scholar
  33. 33.
    Aggarwal A, Sharma DD: Zolpidem withdrawal delirium: a case report. J Neuropsychiatry Clin Neurosci 2010; 22(4):451–45o.PubMedCrossRefGoogle Scholar
  34. 34.
    Freudenreich O, Menza M: Zolpidem-related delirium: a case report. J Clin Psychiatry 2000; 61(6):449–450.PubMedCrossRefGoogle Scholar
  35. 35.
    Miller JM, Kustra RP, Vuong A, Hammer AE, Messenheimer JA: Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs 2008; 68(11):1493–1509.PubMedCrossRefGoogle Scholar
  36. 36.
    Mula M, Sander JW: Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007; 30(7):555–567.PubMedCrossRefGoogle Scholar
  37. 37.
    Yerevanian BI, Choi YM: Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord 2013; 15(5):594–621.PubMedCrossRefGoogle Scholar
  38. 38.
    Grunze HC: The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci 2008; 10(1):77–89.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Bandelow B, Muller P, Gaebel W, Kopcke W, Linden M, Muller-Spahn F, Pietzcker A, Reischies FM, Tegeler J: Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich. Eur Arch Psychiatry Clin Neurosci 1990; 240(2):113–120.PubMedCrossRefGoogle Scholar
  40. 40.
    Minov C, Messer T, Schmauss M: Organische Psychosen; in: Block F, Prüter C, (eds): Heidelberg, Springer Medizin Verlag, 2006, pp 407-420.Google Scholar
  41. 41.
    Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, Schubert CC, Munger S, Fick D, Miller D, Gulati R: The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009; 4:225–233.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Knegtering H, Eijck M, Huijsman A: Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging 1994; 5(3):192–199.PubMedCrossRefGoogle Scholar
  43. 43.
    Prüter C: Demenz; in: Block F, Prüter C, (eds): Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg, Springer Medizin Verlag, 2006, pp 361-383.Google Scholar
  44. 44.
    Foy A, O’Connell D, Henry D, Kelly J, Cocking S, Halliday J: Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol A Biol Sci Med Sci 1995; 50(2):M99–106.PubMedCrossRefGoogle Scholar
  45. 45.
    McKinney PA, Finkenbine RD, DeVane CL: Alopecia and mood stabilizer therapy. Ann Clin Psychiatry 1996; 8(3):183–185.PubMedCrossRefGoogle Scholar
  46. 46.
    Johannessen LC, Patsalos PN: Drug interactions involving the new second- and thirdgeneration antiepileptic drugs. Expert Rev Neurother 2010; 10(1):119–140.CrossRefGoogle Scholar
  47. 47.
    Rambeck B, Wolf P: Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25(6):433–443.PubMedCrossRefGoogle Scholar
  48. 48.
    Flanagan RJ, Dunk L: Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 Suppl 1:27–41.PubMedGoogle Scholar
  49. 49.
    Alvir JM, Lieberman JA: Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55 Suppl B:137–138.PubMedGoogle Scholar
  50. 50.
    Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329(3):162–167.PubMedCrossRefGoogle Scholar
  51. 51.
    Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352(11):1112–1120.PubMedCrossRefGoogle Scholar
  52. 52.
    Strawn JR, Keck PE, Jr., Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164(6):870–876.PubMedCrossRefGoogle Scholar
  53. 53.
    Strawn JR, Keck PE, Jr., Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164(6):870–876.PubMedCrossRefGoogle Scholar
  54. 54.
    Strawn JR, Keck PE, Jr., Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164(6):870–876.PubMedCrossRefGoogle Scholar
  55. 55.
    Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, Brown AJ: Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoproteinderived cholesterol. Pharmacogenomics J 2010; 10(5):396–407.PubMedCrossRefGoogle Scholar
  56. 56.
    Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123(2-3):225–233.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159(6):1055–1057.CrossRefGoogle Scholar
  58. 58.
    Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, doubleblind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160(8):1396–1404.PubMedCrossRefGoogle Scholar
  59. 59.
    Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187:537–543.PubMedCrossRefGoogle Scholar
  60. 60.
    Yood MU, DeLorenze G, Quesenberry CP, Jr., Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L’Italien G: The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009; 18 (9):791–799.Google Scholar
  61. 61.
    Kessing LV, Thomsen AF, Mogensen UB, Andersen PK: Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197(4):266–271.PubMedCrossRefGoogle Scholar
  62. 62.
    Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychoticinduced side effects. World J Biol Psychiatry 2013; 14(1):2–44.PubMedCrossRefGoogle Scholar
  63. 63.
    Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26(6):748–758.PubMedCrossRefGoogle Scholar
  64. 64.
    Byerly M, Suppes T, Tran QV, Baker RA: Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27(6):639–661.PubMedCrossRefGoogle Scholar
  65. 65.
    Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63(12):1121–1128.PubMedCrossRefGoogle Scholar
  66. 66.
    Madhusoodanan S, Parida S, Jimenez C: Hyperprolactinemia associated with psychotropics—a review. Hum Psychopharmacol 2010; 25(4):281–297.PubMedCrossRefGoogle Scholar
  67. 67.
    FDA: Information for Healthcare Professionals: Haloperidol. FDA ALERT 9/2007, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand-Providers/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm
  68. 68.
    Arzneimittelkommission der Deutschen Ärzteschaft: Information über die Änderung der bisher empfohlenen Applikationswege von Haldol®-Janssen-Injektionslösung. AkdÄ Drug Safety Mail 2010–098 5th May 2010, http://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2010-098.html

Copyright information

© Urban & Vogel 2014

Authors and Affiliations

  1. 1.Danuvius Klinik GmbHPfaffenhofen an der IlmDeutschland

Personalised recommendations